{"id":984087,"date":"2026-07-23T09:06:42","date_gmt":"2026-07-23T13:06:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/"},"modified":"2026-07-23T09:06:42","modified_gmt":"2026-07-23T13:06:42","slug":"xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/","title":{"rendered":"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026<\/b><\/p>\n<p class=\"bwalignc\"><b>Conference Call to be Held at 8:30 a.m. ET<\/b><\/p>\n<p class=\"bwalignl\">CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results.<\/p>\n<p>\nInterested parties may pre-register for the call <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F250146676&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=aeb3386cb499234b01e7f8e4ab4d4614\">here<\/a> or via the \u201cEvents\u201d section of the Investor Relations website. It is recommended that attendees register 15 minutes prior to the scheduled webcast.<\/p>\n<p>\nThe webcast, replay and other information related to the event can be accessed on the investor website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fxerispharma.com%2Finvestor-relations&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=https%3A%2F%2Fxerispharma.com%2Finvestor-relations&amp;index=2&amp;md5=281d353dca8769aa699063da1f7eaefe\">https:\/\/xerispharma.com\/investor-relations<\/a>.<\/p>\n<p><b>About Xeris<\/b><\/p>\n<p>\nXeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev<sup>\u00ae<\/sup>, for the treatment of endogenous Cushing\u2019s syndrome; Gvoke<sup>\u00ae<\/sup>, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis<sup>\u00ae<\/sup>, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris\u2019 technology platforms, XeriSol<sup>\u00ae<\/sup> and XeriJect<sup>\u00ae<\/sup>, for its partners.<\/p>\n<p>\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.xerispharma.com&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=www.xerispharma.com&amp;index=3&amp;md5=fc314208de7b171e7b2f7cfe88e0298c\">www.xerispharma.com<\/a>, or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2Fxerispharma%3Flang%3Den&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=064915edf5c2f51c7c5b67286e691f03\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fxeris-pharmaceuticals%2Fposts%2F%3FfeedView%3Dall&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=5293f9adb6df2c81b6f4160c91cd5498\">LinkedIn<\/a>, or <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fxerispharma%2F&amp;esheet=54575074&amp;newsitemid=20260723610212&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=22ff3f55d9d316a42aadb93503ec51bc\">Instagram<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260723610212\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260723610212\/en\/<\/a><\/span><\/p>\n<p><b>Xeris Investor Contact<br \/>\n<\/b><br \/>Allison Wey<br \/>\n<br \/>Senior Vice President, Investor Relations and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:awey@xerispharma.com\">awey@xerispharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Illinois United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Technology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260723610212\/en\/2857563\/3\/Xeris_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 Conference Call to be Held at 8:30 a.m. ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results. Interested parties may pre-register for the call here or via the \u201cEvents\u201d section of the Investor Relations website. It is recommended &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-984087","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 Conference Call to be Held at 8:30 a.m. ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results. Interested parties may pre-register for the call here or via the \u201cEvents\u201d section of the Investor Relations website. It is recommended &hellip; Continue reading &quot;Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T13:06:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026\",\"datePublished\":\"2026-07-23T13:06:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/\"},\"wordCount\":321,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/\",\"name\":\"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-23T13:06:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/","og_locale":"en_US","og_type":"article","og_title":"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Market Newsdesk","og_description":"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 Conference Call to be Held at 8:30 a.m. ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results. Interested parties may pre-register for the call here or via the \u201cEvents\u201d section of the Investor Relations website. It is recommended &hellip; Continue reading \"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-23T13:06:42+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026","datePublished":"2026-07-23T13:06:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/"},"wordCount":321,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/","name":"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-23T13:06:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260723610212r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=984087"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984087\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=984087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=984087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=984087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}